Join the revolution and increase your testosterone levels by a ridiculuous 347%!
Reduce estrogen while increasing testosterone to help you get in the best shape yet
Can be used as a standalone or as a PCT after your cycle.
-Boost Testosterone Levels
-Normalize and Balance Hormones
-Retain your gains
Testavate 500 is an formulation of natural ingredients designed to boost levels by 300 + points and , while simultaneously reducing estrogen levels and avoiding any DHT levels to occur.
Testavate 500's flagship ingredient, Bulbine Natalensis, a potent plant derivative, has been used for centuries in South Africa to enhance strength and libido. Protodioscin, another plant derivative, is included in the formulation to work synergistically with Bulbine to achieve optimal results by elevating leydig cells while achieving anabolism throughout a cycle
Testavate 500 also includes the powerful antioxidants, Milk Thistle, and Resveratrol to combat free radical damage generated by intense training. Testavate 500 also includes 5000iu of Vitamin D3 to promote both a healthy immune system, and a strong skeletal system.
This powerful supplement, will be a cornerstone to the discerning natural athlete's training regimen and a finishing product for the serious bodybuilder that are taking PH type products like pro-hormones.
Testavate Blend- 2525 mg
Blend includes: Protodioscin, Bulbine Natalensis, Milk Thistle, Reservatrol, Long Jack NMDA, Alframomum Melegueta (Seed)
90 Capsules per bottle
Customer Reviews (2)
- Great Product great PriceReview by Mark
Price Value Quality
- Good BoostReview by Big Jay
Price Value Quality
Write Your Own Review
1*Nutraclipse Testavate 500 x 90 caps + 1*Pure L-Arginine AAKG (120 Servings)
1*Nutraclipse Testavate 500 x 90 caps + 1*Genomyx D-Aspartic Acid, 60 Servings - DAA
£56.98 £31.98X1+Aviva Nutrition Super Fruits & Greens (BBE 01/2017)
Experience the AVIVA difference with SUPER FRUITS & GREENS, a superfood revolution.
1*Nutraclipse Testavate 500 x 90 caps + 1*Aviva Nutrition Super Fruits & Greens (BBE 01/2017)